Lake Street Private Wealth LLC Cuts Stock Holdings in Enfusion, Inc. (NYSE:ENFN)

Lake Street Private Wealth LLC lowered its stake in Enfusion, Inc. (NYSE:ENFN) by 38.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,441 shares of the company’s stock after selling 9,559 shares during the quarter. Lake Street Private Wealth LLC’s holdings in Enfusion were worth $159,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Harbor Capital Advisors Inc. lifted its position in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after buying an additional 1,315 shares in the last quarter. Belvedere Trading LLC purchased a new stake in shares of Enfusion during the 3rd quarter worth approximately $114,000. Paloma Partners Management Co purchased a new stake in shares of Enfusion during the 3rd quarter worth approximately $157,000. The Manufacturers Life Insurance Company grew its holdings in shares of Enfusion by 27.7% in the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after purchasing an additional 4,239 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new position in shares of Enfusion in the second quarter valued at $183,000. Institutional investors own 81.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ENFN shares. Stifel Nicolaus increased their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler boosted their price objective on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research note on Monday, December 23rd. Finally, William Blair reaffirmed a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Enfusion presently has an average rating of “Hold” and an average price target of $10.25.

Enfusion Price Performance

Enfusion stock opened at $11.06 on Friday. Enfusion, Inc. has a 1-year low of $7.52 and a 1-year high of $11.38. The company’s 50-day moving average is $10.28 and its 200 day moving average is $9.28. The firm has a market capitalization of $1.42 billion, a P/E ratio of 276.44, a price-to-earnings-growth ratio of 1.58 and a beta of 0.95.

Insider Transactions at Enfusion

In other Enfusion news, CFO Bradley Herring sold 24,443 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $10.61, for a total value of $259,340.23. Following the sale, the chief financial officer now owns 270,503 shares in the company, valued at $2,870,036.83. This trade represents a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Oleg Movchan sold 2,771 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the transaction, the chief executive officer now owns 526,702 shares in the company, valued at approximately $5,335,491.26. The trade was a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 58,041 shares of company stock worth $597,367. 36.44% of the stock is currently owned by company insiders.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.